Stock ELTX ELICIO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Elicio Therapeutics, Inc.

Equities

ELTX

US28657F1030

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
 23:00:00 22/05/2024 BST 		5-day change 1st Jan Change
8.85 USD -0.11% Intraday chart for Elicio Therapeutics, Inc. -5.65% +6.12%
05-23 Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting CI
04-05 Elicio Therapeutics, Inc. to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing Amplify-201 Phase 1 Study of ELI-002 and ElI-008 at the AACR Annual Meeting CI

Business Summary

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). Its ELI-007, is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. Its AMP platform has broad potential applications for the treatment or prevention of cancer, infectious diseases and other diseases.

Number of employees: 32

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 10,284,740 7,239,177 ( 70.39 %) 14,455 ( 0.1405 %) 70.39 %

Shareholders

NameEquities%Valuation
Gkcc LLC
18.72 %
1,915,639 18.72 % 17 M $
Access Industries, Inc. (New York)
4.706 %
481,727 4.706 % 4 M $
Vanguard Group, Inc. (Subfiler)
2.107 %
215,686 2.107 % 2 M $
Jay Venkatesan
1.275 %
130,534 1.275 % 1 M $
CM Management LLC
0.7327 %
75,000 0.7327 % 682 500 $
Geode Capital Management LLC
0.4660 %
47,696 0.4660 % 434 034 $
Robert Connelly
0.4589 %
46,970 0.4589 % 427 427 $
Christopher Haqq
0.3125 %
31,981 0.3125 % 291 027 $
STATE STREET CORPORATION
0.1720 %
17,600 0.1720 % 160 160 $
Meyer Handelman Co. LLC
0.1358 %
13,899 0.1358 % 126 481 $

Company contact information

Elicio Therapeutics, Inc.

451 D Street 5th floor, Suite 501

02210, Boston

+

http://www.elicio.com
address Elicio Therapeutics, Inc.(ELTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.85 USD
Average target price
10 USD
Spread / Average Target
+12.99%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ELICIO THERAPEUTICS, INC. Stock Elicio Therapeutics, Inc.
+6.12% 90.46M
MODERNA, INC. Stock Moderna, Inc.
+69.96% 62.86B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.93% 41.38B
LONZA GROUP AG Stock Lonza Group AG
+45.66% 40.38B
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.64B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.10% 26.46B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.91% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.39% 12.67B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.20% 12.27B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.57% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ELTX Stock
  4. Company Elicio Therapeutics, Inc.